The financial stakes in the biosimilars market are enormous, and an understanding of sequence IP for the underlying technologies and modes of action is key to entry into it, say Henk Heus and Ellen Sherin of GQ Life Sciences.
The 12th annual BIO-Europe Spring conference, to be held in Amsterdam, the Netherlands on March 12 to 14, 2018, will allow key players in the biotech industry to come together, as Catherine Moreno Finan reports.
Forming licensing agreements with other pharmaceutical companies is an important part of Pieris’s strategy, according to Ahmed Mousa, vice president of licensing, IP and legal affairs at the clinical-stage company.
Companies researching and commercialising drugs for rare diseases face unusual challenges in protecting their inventions, as Michael Yamauchi, director and patent counsel at Alexion Pharmaceuticals, tells LSIPR in an interview.
Politics has a huge impact on enforcement in Africa, Asia and the Middle East, a senior corporate counsel at Pfizer has told LSIPR in an interview.
While the impact of the European Medicines Agency’s relocation from London to Amsterdam is unknown, industry and government will try to ensure that the UK remains at the forefront of medicines regulation, says Rachel Bradley of Penningtons Manches.
Thinking about how IP can assist a company long before it has fully developed is essential, says Leda Trivinos of Flagship Pioneering in an interview with LSIPR.
Frazier Healthcare Partners has been responsible for creating and investing in multiple biotech companies, developing products from novel antibiotics to cancer therapies. James Topper, Frazier’s managing general partner, explains the firm’s philosophy.
Major tasks for Carl Gordon of OrbiMed, a healthcare fund, include drug pricing and helping to turn promising ideas into reality, as he tells LSIPR.